Prelude Therapeutics

NSQ:PRLD · US74065P1012

BiotechnologySmall

360

Value35

Profit price66

Cash yield1

Sales & asset price61

Price/Sales70

EV / Gross Profit15

Price/Book97

Quality42

Returns on capital24

Return on Capital25

Cash Return on Capital23

Return on Equity24

Profit margins48

Cash backing49

Accruals87

Owner Earnings Margin10

Growth66

Sales growth91

Profit growth82

Reinvestment78

Price momentum92

Safety50

Debt load23

Debt serviceability8

Refinancing15

Debt Payback1

Liquidity88

Sentiment55

Analyst ratings37

Expectations trend47

Opinion Changes50

Price Target Upside44

Market mood15

Value Creation6/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Prelude Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2016

Employees80

Websitepreludetx.com

ISINUS74065P1012

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

HematologyOncologyBiopharmaPharmaceuticalTherapeutics

Description

Prelude Therapeutics Incorporated (Prelude) is a clinical-stage precision oncology company. The company delivers novel precision cancer medicines to underserved patients. By leveraging the company’s core competencies in cancer biology and medicinal…

Analysis

Middle-of-the-road

Prelude Therapeutics Incorporated is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Prelude Therapeutics with its peers

Tyra Biosciences

NSQ:TYRA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Metagenomi Therapeutics

NSQ:MGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Monte Rosa Therapeutics

NSQ:GLUE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nurix Therapeutics

NMQ:NRIX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

ArriVent BioPharma

NMQ:AVBP

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zymeworks

NSQ:ZYME

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →